Dose adjustment of carboplatin in patients on hemodialysis

Achuta Kumar Guddati, Parijat S. Joy, Creticus P. Marak

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Carboplatin is one of the most prescribed cytotoxic drug, which is extensively used in the treatment regimens of several malignancies. The therapeutic efficiency of carboplatin has been found to correlate the area under curve (AUC). The Calvert formula has been extensively used to determine the dose of carboplatin for a fixed AUC and glomerular filtration rate (GFR). This formula has also been used in patients with end-stage renal disease on hemodialysis by assuming that the GFR is zero. This is applicable to patients who receive hemodialysis within 12-18 h after carboplatin infusion. After the first 24 h, a majority of the carboplatin is bound to proteins is not easily dialyzable and hence continues to remain in the blood stream despite repeated sessions of hemodialysis. We derive a correction factor to calculate the resultant AUC in such patients. The analysis done by using this correction factor shows that the AUC can increase by eightfold in patients who received the adjusted dose but whose hemodialysis was delayed beyond 24 h after infusion. The correction factor proposed here can also be used to calculate the dose adjustment required a priori in patients who may receive delayed hemodialysis. It is also useful to predict the AUC and estimate the resultant toxicity in such patients.

Original languageEnglish (US)
Article number848
JournalMedical Oncology
Volume31
Issue number3
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Carboplatin
Renal Dialysis
Area Under Curve
Glomerular Filtration Rate
Chronic Kidney Failure
Therapeutics
Pharmaceutical Preparations
Neoplasms
Proteins

Keywords

  • AUC
  • Carboplatin
  • Dose
  • Hemodialysis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Hematology
  • Medicine(all)

Cite this

Dose adjustment of carboplatin in patients on hemodialysis. / Guddati, Achuta Kumar; Joy, Parijat S.; Marak, Creticus P.

In: Medical Oncology, Vol. 31, No. 3, 848, 01.01.2014.

Research output: Contribution to journalArticle

Guddati, Achuta Kumar ; Joy, Parijat S. ; Marak, Creticus P. / Dose adjustment of carboplatin in patients on hemodialysis. In: Medical Oncology. 2014 ; Vol. 31, No. 3.
@article{17a5482d2d504cc689f1a32a3aa946b7,
title = "Dose adjustment of carboplatin in patients on hemodialysis",
abstract = "Carboplatin is one of the most prescribed cytotoxic drug, which is extensively used in the treatment regimens of several malignancies. The therapeutic efficiency of carboplatin has been found to correlate the area under curve (AUC). The Calvert formula has been extensively used to determine the dose of carboplatin for a fixed AUC and glomerular filtration rate (GFR). This formula has also been used in patients with end-stage renal disease on hemodialysis by assuming that the GFR is zero. This is applicable to patients who receive hemodialysis within 12-18 h after carboplatin infusion. After the first 24 h, a majority of the carboplatin is bound to proteins is not easily dialyzable and hence continues to remain in the blood stream despite repeated sessions of hemodialysis. We derive a correction factor to calculate the resultant AUC in such patients. The analysis done by using this correction factor shows that the AUC can increase by eightfold in patients who received the adjusted dose but whose hemodialysis was delayed beyond 24 h after infusion. The correction factor proposed here can also be used to calculate the dose adjustment required a priori in patients who may receive delayed hemodialysis. It is also useful to predict the AUC and estimate the resultant toxicity in such patients.",
keywords = "AUC, Carboplatin, Dose, Hemodialysis",
author = "Guddati, {Achuta Kumar} and Joy, {Parijat S.} and Marak, {Creticus P.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/s12032-014-0848-0",
language = "English (US)",
volume = "31",
journal = "Medical Oncology",
issn = "1357-0560",
publisher = "Humana Press",
number = "3",

}

TY - JOUR

T1 - Dose adjustment of carboplatin in patients on hemodialysis

AU - Guddati, Achuta Kumar

AU - Joy, Parijat S.

AU - Marak, Creticus P.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Carboplatin is one of the most prescribed cytotoxic drug, which is extensively used in the treatment regimens of several malignancies. The therapeutic efficiency of carboplatin has been found to correlate the area under curve (AUC). The Calvert formula has been extensively used to determine the dose of carboplatin for a fixed AUC and glomerular filtration rate (GFR). This formula has also been used in patients with end-stage renal disease on hemodialysis by assuming that the GFR is zero. This is applicable to patients who receive hemodialysis within 12-18 h after carboplatin infusion. After the first 24 h, a majority of the carboplatin is bound to proteins is not easily dialyzable and hence continues to remain in the blood stream despite repeated sessions of hemodialysis. We derive a correction factor to calculate the resultant AUC in such patients. The analysis done by using this correction factor shows that the AUC can increase by eightfold in patients who received the adjusted dose but whose hemodialysis was delayed beyond 24 h after infusion. The correction factor proposed here can also be used to calculate the dose adjustment required a priori in patients who may receive delayed hemodialysis. It is also useful to predict the AUC and estimate the resultant toxicity in such patients.

AB - Carboplatin is one of the most prescribed cytotoxic drug, which is extensively used in the treatment regimens of several malignancies. The therapeutic efficiency of carboplatin has been found to correlate the area under curve (AUC). The Calvert formula has been extensively used to determine the dose of carboplatin for a fixed AUC and glomerular filtration rate (GFR). This formula has also been used in patients with end-stage renal disease on hemodialysis by assuming that the GFR is zero. This is applicable to patients who receive hemodialysis within 12-18 h after carboplatin infusion. After the first 24 h, a majority of the carboplatin is bound to proteins is not easily dialyzable and hence continues to remain in the blood stream despite repeated sessions of hemodialysis. We derive a correction factor to calculate the resultant AUC in such patients. The analysis done by using this correction factor shows that the AUC can increase by eightfold in patients who received the adjusted dose but whose hemodialysis was delayed beyond 24 h after infusion. The correction factor proposed here can also be used to calculate the dose adjustment required a priori in patients who may receive delayed hemodialysis. It is also useful to predict the AUC and estimate the resultant toxicity in such patients.

KW - AUC

KW - Carboplatin

KW - Dose

KW - Hemodialysis

UR - http://www.scopus.com/inward/record.url?scp=84892613144&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892613144&partnerID=8YFLogxK

U2 - 10.1007/s12032-014-0848-0

DO - 10.1007/s12032-014-0848-0

M3 - Article

VL - 31

JO - Medical Oncology

JF - Medical Oncology

SN - 1357-0560

IS - 3

M1 - 848

ER -